Dr. John Robert Alm, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1120a Makawao Ave, Makawao, HI 96768 Phone: 808-573-2222 Fax: 760-631-3274 |
News Archive
The cellulose produced by bacteria could be used for artificial blood vessels in the future as it carries a lower risk of blood clots than the synthetic materials currently used for bypass operations, reveals a thesis from the Sahlgrenska Academy at the University of Gothenburg, Sweden.
In honor of National Autism Awareness Month this April, representatives from Autism Society will preside over the NASDAQ Opening Bell. Nicholas Medovitch, an individual with autism, will ring the bell.
Apricus Biosciences, backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT® drug delivery technology and internal pipeline through out-licensing partnerships, today announced that the Company has closed its previously announced securities offering, raising over $9.3 million in gross proceeds. Apricus Bio intends to use the proceeds from this offering for product and technology development and general corporate purposes. Dawson James Securities acted as the exclusive placement agent for the offering.
Boston Scientific Corporation announces U.S. Food and Drug Administration (FDA) approval of the Infinion 16 Percutaneous Lead for its Precision Plus Spinal Cord Stimulator (SCS) System, the first rechargeable SCS device for chronic pain management.
A limitation of organ transplant is acute rejection of the graft by the host immune system. Graft rejection is mediated by the development of CD8+ cytotoxic T cells that target donor MHC class I molecules, and in animal models, these cells have been shown to develop in secondary lymphoid organs.
› Verified 3 days ago